Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · IEX Real-Time Price · USD
46.69
-0.13 (-0.28%)
Mar 28, 2024, 4:00 PM EDT - Market closed
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for RARE stock have an average target of 91.25, with a low estimate of 48 and a high estimate of 133. The average target predicts an increase of 95.44% from the current stock price of 46.69.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for RARE stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 2 | 3 | 3 |
Buy | 7 | 7 | 6 | 6 | 7 | 8 |
Hold | 2 | 2 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 12 | 12 | 10 | 9 | 11 | 12 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
JP Morgan | JP Morgan | Buy Maintains $88 → $92 | Buy | Maintains | $88 → $92 | +97.04% | Mar 18, 2024 |
JP Morgan | JP Morgan | Buy Maintains $84 → $88 | Buy | Maintains | $84 → $88 | +88.48% | Feb 27, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $107 | Buy | Maintains | $107 | +129.17% | Feb 27, 2024 |
Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $110 → $111 | Strong Buy | Maintains | $110 → $111 | +137.74% | Feb 21, 2024 |
Wedbush | Wedbush | Hold Maintains $47 → $48 | Hold | Maintains | $47 → $48 | +2.81% | Feb 16, 2024 |
Financial Forecast
Revenue This Year
523.35M
from 434.25M
Increased by 20.52%
Revenue Next Year
662.03M
from 523.35M
Increased by 26.50%
EPS This Year
-6.58
from -8.25
EPS Next Year
-5.00
from -6.58
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 556.5M | 966.7M | 1.1B | 2.5B | 4.0B |
Avg | 523.4M | 662.0M | 862.2M | 1.6B | 2.4B |
Low | 489.7M | 530.9M | 621.3M | 668.7M | 799.0M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 28.2% | 84.7% | 69.8% | 194.7% | 149.8% |
Avg | 20.5% | 26.5% | 30.2% | 84.5% | 48.7% |
Low | 12.8% | 1.4% | -6.1% | -22.5% | -49.8% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -5.49 | -1.66 | 0.57 | 1.64 | 5.65 |
Avg | -6.58 | -5.00 | -2.81 | 1.59 | 5.49 |
Low | -7.96 | -6.76 | -5.81 | 1.53 | 5.27 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 255.0% |
Avg | - | - | - | - | 244.9% |
Low | - | - | - | - | 231.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.